Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Oct
29
Today In Oncology
AI Shear Wave Elastography Model for Diagnosing Breast Cancer in BI-RADS 3 or 4 Masses
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
Revumenib Approved by FDA for NPM1 AML
Cutaneous Squamous Cell Carcinoma AI Model Rivals Dermatologists in Differentiation Assessment
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo